Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - ciprofloxacin, quantity: 2 mg/ml - injection, intravenous infusion - excipient ingredients: lactic acid; glucose monohydrate; water for injections - aspen ciprofloxacin injection for intravenous infusion is indicated for use in the following. hospitalised adult patients in whom oral ciprofloxacin is indicated but cannot be administered or where the oral form is inappropriate. for the treatment of serious or life-threatening infections due to sensitive organisms involving the following organ systems. lower respiratory tract infections (gram-negative organisms), skin and skin structure, septicaemia, bone and joint, urinary tract. inhalational anthrax (post exposure): to reduce the incidence or progression of disease following exposure to aerosolized bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. if anaerobic

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - ciprofloxacin, quantity: 2 mg/ml - injection, intravenous infusion - excipient ingredients: lactic acid; glucose monohydrate; water for injections - aspen ciprofloxacin injection for intravenous infusion is indicated for use in the following. hospitalised adult patients in whom oral ciprofloxacin is indicated but cannot be administered or where the oral form is inappropriate. for the treatment of serious or life-threatening infections due to sensitive organisms involving the following organ systems. lower respiratory tract infections (gram-negative organisms), skin and skin structure, septicaemia, bone and joint, urinary tract. inhalational anthrax (post exposure): to reduce the incidence or progression of disease following exposure to aerosolized bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. if anaerobic

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - codeine phosphate hemihydrate, quantity: 30 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; magnesium stearate - aspen codeine tablets are indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Ireland - English - HPRA (Health Products Regulatory Authority)

aspen pharma trading limited - nadroparin calcium - solution for injection - 9,500 i.u. anti-xa/1.0 millilitre(s) - heparin group; nadroparin

Ireland - English - HPRA (Health Products Regulatory Authority)

aspen pharma trading limited - nadroparin calcium - solution for injection - 9,500 i.u.anti-xa/1.0 millilitre(s) - heparin group; nadroparin

United Kingdom - English - myHealthbox

aspen pharma trading limited - sulfamethoxazole/trimethoprim - tablets - 80mg/400mg - combinations of sulfonamides and trimethoprim, incl. derivatives - it indicated for: treatment and prevention of pneumocystis jiroveci (p. carinii) pneumonitis; treatment and prophylaxis of toxoplasmosis; treatment of nocardiosis; acute uncomplicated urinary tract infection; acute otitis media; acute exacerbation of chronic bronchitis

United Kingdom - English - myHealthbox

aspen pharma trading limited - sulfamethoxazole/trimethoprim - tablets - 800mg/160mg - combinations of sulfonamides and trimethoprim, incl. derivatives - it is indicated for: treatment and prevention of pneumocystis jiroveci (p. carinii) pneumonitis; treatment and prophylaxis of toxoplasmosis; treatment of nocardiosis; acute uncomplicated urinary tract infection; acute otitis media; acute exacerbation of chronic bronchitis

United Kingdom - English - myHealthbox

aspen pharma trading limited - sulfamethoxazole/trimethoprim - suspension - 80mg/400 mg per 5 ml - combinations of sulfonamides and trimethoprim, incl. derivatives - it is indicated for: treatment and prevention of pneumocystis jiroveci.(p. carinii) pneumonitis; treatment and prophylaxis of toxoplasmosis; treatment of nocardiosis; acute uncomplicated urinary tract infections; acute otitis media; acute exacerbation of chronic bronchitis

United Kingdom - English - myHealthbox

aspen pharma trading limited - sulfamethoxazole/trimethoprim - suspension - 40mg/200mg per 5ml - combinations of sulfonamides and trimethoprim, incl. derivatives - it is indicated for: treatment and prevention of pneumocystis jiroveci (p. carinii) pneumonitis treatment and prophylaxis of toxoplasmosis treatment of nocardiosis acute uncomplicated urinary tract infection acute otitis media acute exacerbation of chronic bronchitis

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - fluconazole, quantity: 200 mg - injection, solution - excipient ingredients: sodium chloride; water for injections - fluconazole injection is indicated for the following conditions but should be used only when fluconazole cannot be administered orally: 1. treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note: data suggest that the clinical efficacy of fluconazole is lower than that of amphotericin b in the treatment of the acute phase of cryptococcal meningitis. 2. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with acquired immune deficiency syndrome (aids). 3. treatment of oropharyngeal and oesophageal candidiasis in patients with aids and other immunosuppressed patients. 4. secondary prophylaxis of oropharyngeal candidiasis in patients with human immunodeficiency virus (hiv) infection. 5. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note: it remains to be shown that fluconazole is as effective as amphotericin b in the treatment of serious and life-threatening candida infections. until such d